*To the Editor:* Recent observations by Wambier et al[@bib1] suggest that men with pattern baldness are at high risk for severe symptomatic COVID-19 infection. Two preliminary studies[@bib1] ^,^ [@bib2] noted high rates of androgenic alopecia in men hospitalized for severe COVID-19. Both of these uncontrolled observational studies were limited by small sample size. To further evaluate this intriguing observation, we examined severity of hair loss in 1941 hospitalized male patients tested for COVID-19 using data from the UK Biobank. We conducted multivariable logistic regression analysis, where the outcome was a positive COVID-19 test result, and the main variable of interest was severity of balding. Other variables accounted for were age, body mass index (BMI), hypertension, dyslipidemia, and diabetes.

From 2006 to 2010, the UK Biobank recruited approximately 500,000 individuals from the United Kingdom and collected detailed information about their medical history. Informed consent was obtained from all participants registered with the UK Biobank. Data were regularly updated, and the most recent data from 2019 were used for all covariates analyzed in our study. During the original intake, 226,938 men chose from 1 of 4 options that best characterized their hair loss using images adapted from the Hamilton-Norwood scale.[@bib3] Options included the following text: pattern 1, no hair loss; pattern 2, slight hair loss; pattern 3, moderate hair loss; and pattern 4, severe hair loss.[@bib4] COVID-19 testing was carried out on symptomatic patients per National Health Service guidelines.[@bib5]

Descriptive frequencies for COVID-19 results, balding patterns, age, and BMI are reported in [Table I](#tbl1){ref-type="table"} . The cohort included 1605 patients who tested negative for COVID-19 and 336 patients who tested positive. Mean age and BMI were similar between the 2 groups. As shown in [Table I](#tbl1){ref-type="table"}, COVID-19 positivity trended higher with increasing baldness. Of the 592 patients reporting pattern 1, 15.03% tested positive. Of the 404 patients reporting pattern 2, 16.83% tested positive. Of the 551 patients reporting pattern 3, 18.15% tested positive. Of the 394 patients reporting pattern 4, 20.05% tested positive.Table IDescriptive frequencies for COVID-19 testing results, balding patterns, age, and BMIVariableCOVID-19 (−) test resultCOVID-19 (+) test resultTotal, n1605336Pattern 1, n (%)503 (84.97)89 (15.03)Pattern 2, n (%)336 (83.17)68 (16.83)Pattern 3, n (%)451 (81.85)100 (18.15)Pattern 4, n (%)315 (79.95)79 (20.05)Age, y, mean59.1359.03BMI, kg/m^2^, mean28.6729.11[^1]

Odds ratios and corresponding confidence intervals for balding patterns are shown in [Table II](#tbl2){ref-type="table"} . When compared to pattern 1, patients who reported pattern 4 were significantly more likely to test positive for COVID-19 in the hospital (adjusted odds ratio, 1.408; 95% confidence interval, 1.004-1.972; *P* = .0468). Neither patterns 2 nor 3 reached significance from pattern 1 in rates of positive COVID-19 test results. None of the covariates were associated with a positive COVID-19 test result.Table IIOdds ratios and confidence intervals for balding patterns and covariates from a multivariable logistic regression analysis where the outcome is a positive COVID-19 test result[∗](#tbl2fnlowast){ref-type="table-fn"}EffectOdds Ratio (95% CI)*P* valuePattern 2 vs 11.144 (0.808-1.613).4454Pattern 3 vs 11.271 (0.928-1.744).1362Pattern 4 vs 11.408 (1.004-1.972).0468Age0.995 (0.979-1.011).5179BMI1.014 (0.987-1.041).3062Hypertension vs no hypertension0.941 (0.714-1.246).6679Dyslipidemia vs no dyslipidemia1.240 (0.960-1.602).0993Diabetes vs no diabetes1.041 (0.721-1.482).8273[^2][^3]

Our study compared a large sample of hospitalized COVID-19--positive patients to a control group of hospitalized COVID-19--negative patients and thus builds on and supports the observations of Wambier et al.[@bib1] A notable limitation of our work is that balding data were self-reported. Although the exact mechanism remains unknown, severe androgenic alopecia seems to be associated with hospitalization for COVID-19. The large effect of baldness on the risk of COVID-19 suggests that the presence of severe baldness may help clinicians and public health authorities identify and protect those at greatest risk.
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[^1]: *BMI*, Body mass index.
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[^3]: All statistical analyses were performed with SAS 9.4 (SAS Institute, Cary NC).
